Pharmaceuticals News and Research

RSS

GlaxoSmithKline to acquire Reliant Pharmaceuticals

GlaxoSmithKline and Reliant Pharmaceuticals Inc. have announced that they had reached an agreement under which Reliant will be acquired by GSK for $1.65 billion (800 million pounds Sterling) in cash.

21 Nov 2007

Lenalidomide - dexamethasone combination effective against multiple myeloma

Pairing a new thalidomide derivative with a steroid slows progress of multiple myeloma, an incurable bone marrow cancer, and prolongs the lives of patients who have relapsed from previous treatment, researchers report in the Nov. 22 New England Journal of Medicine.

21 Nov 2007

Barr Pharmaceuticals confirms patent challenge of Focalin XR

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed for Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules, 5mg, 10mg, 15mg & 20mg. Focalin XR is manufactured for the U.S. for Novartis Pharmaceuticals Corporation by Elan Holdings Inc.

21 Nov 2007

Report on new therapies and vaccines for HIV/AIDS

Pharmaceutical researchers are testing 92 medicines and vaccines to treat or prevent HIV/AIDS and related conditions, according to a report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

21 Nov 2007

Early warning for anti-smoking drug Chantix

The drug watchdog in the United States, the Food and Drug Administration (FDA), has expressed concerns regarding the anti-smoking drug Chantix.

21 Nov 2007

New non-addictive pain-killers

Two University of Adelaide pharmacologists working with one the world's leading neuroscientists have helped pave the way for the development of new pain-killing drugs that are not addictive.

20 Nov 2007

Schering-Plough acquires Organon BioSciences

Schering-Plough Corporation has announced that it has completed the acquisition of Organon BioSciences N.V., creating a stronger combined company with broader human and animal health portfolios, an enhanced pipeline and increased R&D capabilities. Schering-Plough's agreement to acquire Organon BioSciences was announced on March 12, 2007.

20 Nov 2007

Managing the chronic care of patients is not being captured in today's reimbursement system

Full-time physicians spend an average of one full day a week providing services for patients that are not reimbursed by Medicare, according to a new study conducted by Jeffrey Farber, MD, Assistant Professor of Geriatrics at The Mount Sinai Medical Center, and published the journal Annals of Internal Medicine.

19 Nov 2007

U.S. approval of Nexavar (sorafenib) for inoperable liver cancer

The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable.

19 Nov 2007

New device for screening potential new drug compounds

A new device invented by researchers at the University of Virginia could save pharmaceutical companies significant time and money in screening potential new drug compounds.

19 Nov 2007

Anti-cancer drug made from soil bacteria

Scientists from the Helmholtz Centre for Infection Research (HZI) have discovered a class of natural substances that are produced by soil bacteria and prevent somatic cells from dividing.

19 Nov 2007

Subcutaneous administration of an antiemetic for treating vomiting caused by chemotherapy

The subcutaneous administration of granisetron, an antiemetic pharmaceutical drug (suitable for control of vomiting), achieves similar blood concentrations to those administered intravenously.

19 Nov 2007

Pfizer to acquire Coley Pharmaceutical Group

Pfizer has announced that it has entered into an agreement to acquire Coley Pharmaceutical Group, a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.

19 Nov 2007

MIT researchers devised novel way to create tiny colonies of living human liver cells that model full-sized organs

Liver toxicity is one of the main reasons pharmaceutical companies pull drugs off the market. These dangerous drugs slip through approval processes due in part to the shortcomings of liver toxicity tests. Existing tests rely on liver cells from rats, which do not always respond to toxins the way human cells do. Or they rely on dying human cells that survive for only a few days in the lab.

19 Nov 2007

Prescription medication dosages often incorrect for obese patients

As if severely overweight people didn't already have enough health concerns, experts are raising another red flag - the possibility that some of their prescription medications, especially antibiotics, may not be prescribed at the appropriate dosage and could be ineffective.

16 Nov 2007

Drug to treat children with bipolar disorder gets priority review

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

15 Nov 2007

GlaxoSmithKline implements changes to the US product label for Avandia

GlaxoSmithKline announced today that it is implementing changes to the US product label for Avandia(R) (rosiglitazone maleate), based on an extensive and thorough review by the FDA of myocardial ischemia data on Avandia, the most widely studied oral anti-diabetic medicine available.

15 Nov 2007

Petition aims to stem the flood of dangerous drugs reaching Americans

In a petition filed with the U.S. Food and Drug Administration, an international coalition of scientists and doctors seeks to compel the agency to stem the flood of dangerous drugs reaching American consumers by mandating the use of scientifically superior non-animal testing methods when those alternatives exist.

15 Nov 2007

Breakthrough innovation for high sensitivity TB and Malaria diagnostics

At this year's 39th World Forum for Medicine in Dusseldorf (MEDICA, November 14-17), Partec, a globally leading developer, manufacturer and provider of dedicated diagnostic solutions in the response to HIV/AIDS, Tuberculosis and Malaria is presenting a breakthrough innovation for high sensitivity TB and Malaria diagnostics in low- and middle-income countries.

15 Nov 2007

Understanding diversity in disease - new routes to prevention, diagnosis and treatment

The Medical Research Council (MRC), the National Institute for Health Research (NIHR) and the health research departments in Northern Ireland, Scotland and Wales have launched a joint initiative of more than £6millon to identify small carefully defined groups of patients to help researchers detect, treat or prevent diseases.

14 Nov 2007